Sustainable and equivalent improvements in symptoms and functional well‐being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13716
Abstract: The PRIORITIZE trial (clinicaltrials.gov: NCT02786537) was the first comparative effectiveness study to directly compare ledipasvir/sofosbuvir (LDV/SOF) and elbasvir/grazoprevir (EBR/GZR) for the treatment of chronic hepatitis C virus (HCV). A secondary aim of this study was… read more here.
Keywords: ldv sof; functional well; trial; symptoms functional ... See more keywords